. The prevalence of the MetS is higher in obese persons even when the role of high waist circumference is factored out ( 14 ) . However, it is also true that many obese persons show little or no metabolic alterations ( 15 , 16 ) and many nonobese people (body mass index [BMI] <30 kg/m 2 ) display characteristic features of the MetS ( 16 -18 ) . Because few studies have examined the independent and joint associations of obesity and the MetS with physical function, whether obesity " per se " or its metabolic consequences constitutes the primary threat to mobility is unknown.
Given the known biomechanical consequences of excess weight, we hypothesize that among initially well-functioning older adults, obesity is a strong independent risk factor for mobility limitation, and the presence of the MetS confers additional risk because it is associated with excess cardiovascular morbidity. Because both the obesity and the MetS are associated with a proinfl ammatory state ( 19 , 20 ) , which also poses a threat to physical function and mobility ( 21 ) , we hypothesize that elevated infl ammatory markers is one of the mechanisms that account for the association between obesity, the MetS, and mobility limitation. Thus, this prospective study aims to examine the independent and joint associations of obesity and the MetS with risk of developing mobility limitations and the role of infl ammatory markers in mediating these associations in older adults.
M ethods

Study Population
The Health, Aging, and Body Composition (Health ABC) Study is a longitudinal cohort study consisting of 3,075 well-functioning, 70-to 79-year-old black and white men and women ( 22 , 23 ) . Participants were identifi ed from a random sample of white Medicare benefi ciaries and all age-eligible community-dwelling black residents in designated ZIP code areas surrounding Memphis, Tennessee, and Pittsburgh, Pennsylvania. Participants were eligible if they reported no diffi culty walking one quarter of a mile, going up 10 steps without resting, or performing basic activities of daily living. Participants were excluded if they reported a history of active treatment for cancer in the prior 3 years, planned to move out of the study area within 3 years, or were enrolled in a lifestyle intervention.
Baseline data, collected between April 1997 and June 1998, included an in-person interview and a clinic-based examination, with evaluation of body composition, clinical and subclinical diseases, and physical functioning. Six and a half years of follow-up was used for this study. Of the 3,075 participants, we excluded those missing data on the MetS ( n = 39) or mobility limitation ( n = 2) and those who died within the fi rst 6 months ( n = 11) or those who were underweight (BMI <18.5 kg/m 2 ) at baseline ( n = 39), yielding a sample of 2,984 persons. All participants signed informed written consent forms approved by the institutional review boards of both clinical sites.
Adiposity
Body weight was measured using a standard balance beam scale to the nearest 0.1 kg. Height was measured barefoot to the nearest 0.1 cm using a stadiometer (Holtain Ltd., Crymych, UK). BMI was calculated as weight divided by height squared (kilogram per square meter). Obesity was defi ned as BMI greater than or equal to 30 kg/m 2 ( 3 ). Waist circumference was measured with a fl exible plastic tape measure to the nearest 0.1 cm at the level of the largest circumference at the end of expiration.
Metabolic Alterations and the MetS
MetS was defi ned following the updated National Cholesterol Education Program Adult Treatment Panel III defi nition in 2005 ( 24 ) as the presence of three or more of the following: (a) waist circumference greater than or equal to 102 cm for men and greater than or equal to 88 cm for women, (b) triglyceride level greater than or equal to 150 mg/dL or currently on drug treatment for high triglyceride, (c) high-density lipoprotein (HDL) cholesterol less than 40 mg/dL for men and less than 50 mg/dL for women or currently on drug treatment for low HDL cholesterol, (d) systolic blood pressure greater than or equal to 130 and/or diastolic blood pressure 85 mmHg or using antihypertensive medication, and (e) fasting glucose greater than or equal to 100 mg/dL or using antidiabetic medication. Systolic and diastolic blood pressures were determined using a conventional mercury sphygmomanometer with the participant in a seated position. Blood samples were drawn after an overnight fast and analyzed for triglyceride and HDL cholesterol using a chemical analyzer (Vitros 950; Johnson & Johnson, Raritan, NJ). Plasma glucose was determined using the automated glucose oxidase reaction (YSI 2300 Glucose Analyzer; Yellow Springs Instruments, Yellow Springs, OH).
Incident Mobility Limitation
All the participants were free of mobility limitation at baseline. Incident mobility limitation was defi ned as a selfreport of any diffi culty walking one quarter of a mile or climbing 10 steps at two consecutive semiannual follow-up assessments conducted for more than 6.5 years. Follow-ups occurred every 6 months, alternating between clinic visits (12, 24, 36, 48, 60 , and 72 months after baseline) and telephone interviews (6, 18, 30, 42, 54, 66 , and 78 months after baseline). It was required that mobility limitation needed to be present at two consecutive assessments because this selects participants with chronic functional limitation rather than those with temporary mobility limitation due to acute events or traumas.
Infl ammatory Markers
A proinfl ammatory state may represent one pathway through which obesity and the MetS infl uence on muscle strength and physical function decline ( 19 , 21 ) . Measures for the proinfl ammatory markers interleukin (IL)-6 and tumor necrosis factor (TNF)-a and for C-reactive protein (CRP) were obtained from frozen stored plasma or serum. Fasting blood samples were obtained in the morning, and after processing, the specimens were aliquoted into cryovials, frozen at − 70°C, and shipped to the Health ABC Core Laboratory at the University of Vermont. Circulating levels of IL-6, TNF-a , and CRP were all measured in duplicate. Serum IL-6 and plasma TNF-a were measured by Quantikine HS ELISA Kits (R&D Systems, Minneapolis, MN). The coeffi cients of variation were 10.3% for IL-6 and 15.8% for TNF-a . Plasma levels of CRP were measured using enzyme-linked immunosorbent assay with anti-CRP antibodies (Calbiochem, San Diego, CA) with a coeffi cient of variation of 8.0%. There were some missing values in infl ammatory markers, CRP ( n = 8), IL-6 ( n = 133), and TNF-a ( n = 171), which were taken into account in the analysis.
Covariates
Age, race (white or black), sex, study site (Memphis or Pittsburgh), educational level (<12, 12, or >12 years), smoking status (current, former smoker, or never-smoker), alcohol consumption (none, <1 drink/d, or ≥ 1 drink/d), physical activity, and chronic conditions were all considered as possible confounders of the association of obesity, MetS, and incident mobility limitation. Physical activity of the past 7 days was assessed by questionnaire during an interview ( 25 ) . Time spent climbing stairs, walking for exercise, walking for other purposes, aerobics, weight or circuit training, highintensity exercise activities, and moderate-intensity exercise activities were obtained as well as information on the intensity level at which each activity was performed. A metabolic equivalent value was assigned to each activity and intensity combination and was used to calculate the number of kilocalories per week spent on those activities ( 26 ) .
Presence of lung disease (asthma, chronic bronchitis, emphysema, or chronic obstructive pulmonary disease), heart disease (coronary heart disease or congestive heart failure), cerebrovascular disease, peripheral arterial disease, and osteoarthritis (hip or knee osteoarthritis) was determined using standardized algorithms considering self-reported physician-diagnosed disease and use of medications. Depressed mood was assessed with the Center for Epidemiological Studies-Depression scale. A cutoff score of 16 was used as a criterion for major depressive symptoms ( 27 ) .
Statistical Analyses
Baseline characteristics of the study population are reported by sex according to obesity (yes or no) and the MetS (yes or no) groups as mean and median values and standard deviations for continuous variables and proportions for categorical variables. Comparisons within nonobese and obese groups were examined with chi-square test for categorical variables, Kruskal -Wallis test for skewed continuous variables, and t test for normally distributed continuous variables. The outcome of this study was incident mobility limitation. Person-time for each participant was calculated from the date of the baseline examination to the date of the fi rst of the two consecutive self-reported mobility limitations, date of death, or date of the last study contact, whichever came fi rst. After assessing the proportionality assumption with the interactions with time (log transformed), KaplanMeier survival function plots and Cox proportional hazard regression models were used to examine the individual and combined associations of obesity and the MetS on time to incident mobility limitation. Analyses were adjusted for covariates statistically associated with incident mobility limitation or with obesity and MetS, including age, race, study site, education, physical activity, smoking, alcohol use as well as lung, heart, peripheral arterial disease, cerebrovascular disease, osteoarthritis, and depression. The mediating role of infl ammatory markers on the association between obesity and MetS groups and mobility limitation was examined by adding infl ammatory markers in the fully adjusted Cox proportional hazard regression models (Model 2, Table 4 ). The proportional reductions in hazard ratios (HRs) were calculated based on the HRs in Model 2 and Model 3 ( Table 4 ) . A signifi cant two-way interaction of sex and obesity and MetS groups on mobility limitation was found ( p < .001); thus, analyses were stratifi ed by sex. The interaction of race and obesity and MetS groups on mobility limitation was not signifi cant. Analyses were performed using SAS 9.1 Statistical Package (SAS Institute, Inc., Cary, NC).
R esults
The mean age of the study population was 73.6 years ( SD = 2.9), 51% were women and 59% were white race. Baseline characteristics according to obesity and the MetS status are shown in Table 1 for women and in Table 2 for men. Overall, 42% of women and 53% of men were nonobese and did not have the MetS, and 28% of nonobese women and 25% of nonobese men were classifi ed as having the MetS. A small number of obese participants did not have the MetS, 9% of women and 7% of men. Last, 21% of women and 15% of men had both the obesity and the MetS.
Over 6.5 years of follow-up, 55% of the women and 44% of the men developed mobility limitation. Participants excluded from analyses, due to missing data, were more likely to be women ( p = .03) and current smokers ( p < .001) and less likely to have the MetS ( p < .001). They did not differ with respect to obesity ( p = .70) or incident mobility limitation ( p = .34).
Associations of obesity and the MetS on the risk of developing mobility limitation are explored in Table 3 . In women, obesity and the MetS independently predicted mobility limitation after adjusting for demographics, lifestyle factors, and prevalent disease (obesity: HR = 1.62, 95% confi dence interval [CI] = 1.37 -1.91; MetS: HR = 1.35, 95% CI = 1.16 -1.58). In men, obesity was independently associated with incident mobility limitation (HR = 1.43, 95% CI = 1.17 -1.75), but the MetS was not (HR = 1.02, 95% CI = 0.85 -1.22). Adjustment for CRP, IL-6, and TNF-a attenuated the associations especially between the MetS and the mobility limitation. The proportional reductions in HRs from Model 2 to Model 3 were 4% in women and 5% in men for obesity and 14% in women and 10% in men for the MetS.
We found a signifi cant interaction between the obesity and the MetS on risk of developing mobility limitation in women ( p = .046) but not in men ( p = .23), which led us to conduct further analyses considering separately the association of different combinations of obesity and the MetS on the risk of developing mobility limitation. Figures 1 and 2 provide Kaplan -Meier survival curves to illustrate the different patterns of risk of developing mobility limitation among nonobese and obese participants with and without the MetS.
In Table 4 , risk of incident mobility limitation according to obesity and the MetS status is studied in more detail. In women, the adjusted risk of incident mobility limitation (Model 2) was progressively greater in nonobese persons with the MetS (HR = 1.49, 95% CI = 1.24 -1.80), obese persons without the MetS (HR = 1.95, 95% CI = 1.51 -2.53), and obese persons with the MetS (HR = 2.16, 95% CI = 1.78 -2.63) relatively to nonobese participants without the MetS. However, obese women did not signifi cantly differ in their risk of developing mobility limitation according to presence of the MetS. In men, obesity and the MetS separately and together were associated with greater risk of incident mobility limitation compared with no obesity and no MetS in models adjusting for demographics. After adjusting for lifestyle factors and prevalent diseases, nonobese men with the MetS no longer had increased risk of developing mobility limitation compared with nonobese men without the MetS. In addition, the adjusted risks for incident mobility limitation were 1.64 (95% CI = 1.19 -2.25) for obese without the MetS and 1.41 (95% CI = 1.12 -1.78) for obese with the MetS.
Finally, the role of infl ammatory markers on the association between combination of obesity and the MetS and mobility limitation risk was examined in Model 3. The adjustment for CRP, IL-6, and TNF-a , in addition to other covariates, attenuated the risk of incident mobility limitation especially among nonobese and obese persons with the MetS. The proportional reductions in HRs from Model 2 to Model 3 in nonobese with the MetS, obese without the MetS, and obese with the MetS were 15%, 6%, and 17% for women and 10%, 6%, and 14% for men, respectively.
D iscussion
In this study, the individual and joint associations of obesity and the MetS on incident mobility limitation were examined in initially well-functioning older adults for more than 6.5 years. Both the obesity and the MetS independently predicted the risk of developing mobility limitation in women, but obesity only and not the MetS predicted the development of mobility limitation in men. Furthermore, having the MetS increased the risk of developing mobility limitation in nonobese women, but in obese women and men, the MetS did not signifi cantly increase the risk of mobility limitation beyond the effects of obesity.
These results confi rm earlier fi ndings on the association between obesity and mobility limitation in old age ( 4 -7 ) Notes : BMI = body mass index; CI = confi dence interval; HR = hazard ratio; MetS = metabolic syndrome. Model 1: Adjusted for age, race, study site, and education. Model 2: Model 1 + adjusted for physical activity, smoking, alcohol use, lung disease, heart disease, peripheral arterial disease, cerebrovascular disease, osteoarthritis, and depression. Model 3: Model 2 + adjusted for C-reactive protein, interleukin-6, and tumor necrosis factor-a . Model 4: Model 2 + interaction term Obesity × MetS.
and further support the notion that both the obesity ( 4 , 28 , 29 ) and the MetS seem to expose women to greater risk of mobility limitation than men ( 10 , 29 ) . As far as we know, this is the fi rst study to report that obesity per se independent of its metabolic consequences is a stronger risk factor for mobility limitation in older obese adults. Thus, we cannot compare our fi ndings with past work.
It has been suggested that obese persons are not a homogeneous group and that the effect of obesity on health may be substantially different when obesity is associated with metabolic dysregulation ( 15 , 16 ) . Previous studies have shown a higher risk of cardiovascular events and mortality among obese persons with metabolic alterations ( 30 -32 ) . Interestingly, although we identifi ed a subgroup of obese persons who did not have the MetS, sometimes referred to as " metabolically healthy obese, " their adjusted risk for mobility limitation was similar as the risk of obese persons who additionally had the MetS. A possible interpretation of our fi ndings is that obesity-related factors other than metabolic consequences are more important in increasing the risk of mobility limitation. For example, excess body weight can cause biomechanical stress on the lower extremity joints leading to pain, osteoarthritis, reduced physical activity, and impaired muscle strength, all of which can predispose an individual to mobility limitation ( 33 , 34 ) . In addition, in older obese persons, the lower extremity muscle strength ( 35 ) or cardiorespiratory fi tness may be inadequate to perform weight-bearing activities without diffi culties.
However, when interpreting our fi ndings, it must be emphasized that the prevalence of metabolically healthy obese was relatively low (9% of women and 7% of men) in the present study population; thus, we may lack power to show signifi cant difference in the risk of mobility limitation between obese persons with and without the MetS. Another explanation for the nonsignifi cant effect of the MetS among obese participants is selective survival. Although there was no difference in survival among those who entered the study, it is possibly that due to the strict inclusion criteria of the Health ABC Study and the relatively older age of the study participants, obese persons with more serious obesityrelated consequences, including the MetS and related cardiovascular conditions, were excluded from this study. Thus, the effect of obesity and MetS on incident mobility limitation may have been underestimated in this study. Future studies in a general population, including younger participants, are needed to confi rm our fi ndings.
Although the presence of the MetS did not present additional risk of mobility limitation in obese participants, nonobese women with the MetS had 1.5 times higher risk of developing mobility limitation compared with those without the MetS. In nonobese men, the MetS did not increase risk of mobility limitation. Previous studies have shown that the MetS is associated with poorer physical functioning and predicts the development of mobility limitation ( 10 -12 ) , but the effect of general obesity (measured with BMI) on the association of the MetS and mobility limitation was not addressed in these studies. Potential explanation for the sex difference in the present study is that women and men exhibit a different pattern of factors that constitutes the MetS. Nearly 90% of nonobese women with the MetS have high waist circumference, whereas in men, the corresponding proportion is 59%. As abdominal obesity, independent of general obesity, is a known risk factor for mobility limitation ( 4 , 36 ) and because mobility limitation is more prevalent in women, this may explain the found differences between men and women.
Finally, our study suggests that elevated infl ammatory markers partly explain the association between obesity, the MetS, and mobility limitation. The role of heightened infl ammatory state was especially clear in explaining the additional mobility limitation risk related to the MetS. This is in accordance with current knowledge about the association of chronic subclinical infl ammation with both the MetS ( 20 , 37 , 38 ) and the mobility limitation ( 21 ) . The role of infl ammation as a risk factor of functional decline has proven to be very important. Increasing evidence suggests that proinfl ammatory cytokines have catabolic effects on muscle, thus decreasing muscle mass and strength ( 21 , 23 , 39 ) and further predisposing older people to functional decline ( 21 , 40 ) .
In conclusion, this prospective study provides evidence that obesity itself, independent of its metabolic consequences, is a risk factor for mobility limitation among obese older adults. In addition, having the MetS increases the risk of functional decline only in nonobese women. Our study implies that it is important to recognize the MetS Notes: CI = confi dence interval; HR = hazard ratio; MetS = metabolic syndrome. Model 1: Adjusted for age, race, study site, and education. Model 2: Model 1 + adjusted for physical activity, smoking, alcohol use, lung disease, heart disease, peripheral arterial disease, cerebrovascular disease, osteoarthritis, and depression. Model 3: Model 2 + adjusted for C-reactive protein, interleukin-6, and tumor necrosis factor-a .
in the nonobese population, especially in women. Furthermore, in addition to lifelong control of healthy body weight, interventions targeting nonmetabolic consequences of obesity, such as reduction of pain, treatment of lower extremity joint problems, improvement of muscle strength, and cardiorespiratory fi tness, may be useful in preventing and delaying mobility decline in older obese adults.
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